About Neovacs
Neovacs is a French biotechnology company focused on active immunotherapy for autoimmune and inflammatory diseases. Using its proprietary technology platform, the company researches and develops Kinoids, drug-candidates which aim to treat disease by inducing an antibody response in the patient.
Neovacs currently focuses its development efforts on two Kinoids:
- TNF-Kinoid is currently developped for Crohn’s disease and Rheumatoid Arthritis
- IFNα-Kinoid is currently developped for the lupus disease
Neovacs has unveiled very exciting clinical data targeting three high potential diseases; they were also presented at major international congresses during 2011
With TNF-Kinoid :
- Phase I/II results in Crohn’s disease have been presented at DDW-Chicago on May 2011. The phase II study is ongoing : the study’s objective is to evaluate the therapeutic efficacy of TNF-Kinoid versus placebo in Crohn’s disease patients having become resistant to anti-TNF drugs. (see press release)
- Phase II results in Rheumatoid Arthritis (see press release)
With IFNα-Kinoid :
- Phase I/IIa results in lupus patients have been presented at the ACR Meeting-Chicago on November 2011.(see press release)
